CANF (Can Fite Biopharma) Tax Rate %: 0.00% (As of Dec. 2025)


CANF Can Fite Biopharma Ltd CANF
60 GF Score
Price $3.91
GF Value $6.33
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Can Fite Biopharma Tax Rate %?

Can Fite Biopharma CANF -15.55% 60 Tax Rate % is 0.00% as of Dec. 2025. GuruFocus rates CANF with a GF Score™ of 60/100 and a GF Value™ of $6.33 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Can Fite Biopharma's Tax Expense for the six months ended in Dec. 2025 was $0.00 Mil. Can Fite Biopharma's Pre-Tax Income for the six months ended in Dec. 2025 was $-4.95 Mil. Therefore, Can Fite Biopharma's Tax Rate % for the quarter that ended in Dec. 2025 was 0.00%.

Can Fite Biopharma Tax Rate % Related Terms

Can Fite Biopharma Tax Rate % Historical Data

* Premium members only.

The historical data trend for Can Fite Biopharma's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Can Fite Biopharma Tax Rate % Chart

Can Fite Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Rate %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Can Fite Biopharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CANF
60GF Score
Can Fite Biopharma Ltd CANF
Tax Rate % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Can Fite Biopharma Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Can Fite Biopharma's Tax Rate % for the fiscal year that ended in Dec. 2025 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2025 )/Pre-Tax Income (A: Dec. 2025 )
=0/-9.828
=0.00 %

Can Fite Biopharma's Tax Rate % for the quarter that ended in Dec. 2025 is calculated as

Tax Rate %=Tax Expense (Q: Dec. 2025 )/Pre-Tax Income (Q: Dec. 2025 )
=0/-4.952
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Rate % →
What does a Tax Rate % of 0.00% mean?
Can Fite Biopharma (CANF) has a Tax Rate % of 0.00% as of Dec. 2025.
Is Can Fite Biopharma's Tax Rate % too high?
Can Fite Biopharma's current Tax Rate % is 0.00%. Overall, Can Fite Biopharma has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's Tax Rate % compare to VRTX and REGN?
Can Fite Biopharma's Tax Rate % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Rate % for a Biotechnology company?
A good Tax Rate % depends on the Biotechnology industry context. However, Tax Rate % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Rate % mean?
A high Tax Rate % can signal that a stock is expensive relative to its fundamentals. Can Fite Biopharma's current Tax Rate % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.33, compared to a current price of $3.91 — trading 38.2% below its estimated fair value. The current Tax Rate % is 0.00%. Can Fite Biopharma's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Rate % calculated?
Tax Rate % is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current Tax Rate % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Can Fite Biopharma (CANF) Overvalued in 2026?

Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued. The current stock price of $3.91 is trading 38.2% below its estimated GF Value™ of $6.33. GuruFocus considers Can Fite Biopharma to be Significantly Overvalued.

Key valuation signals for CANF:

  • Tax Rate %: 0.00%
  • GF Value™: $6.33 vs. price of $3.91 (38.2% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Can Fite Biopharma Business Description

Other Exchanges CANF:Israel
Address 26 Ben Gurion Street, Ramat Gan, ISR, 5257346
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
60GF Score

Get the complete analysis for CANF

Tax Rate % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.91
Price
$6.33
GF Value